$799.09 – $4,199

4th International Conference on Drug Discovery, Designing and Development...

Event Information

Share this event

Date and Time



Executive Airport Plaza Hotel & Conference Centre

7311 Westminster Highway , Richmond, BC

Vancouver, Canada


View Map

Refund Policy

Refund Policy

No Refunds

Event description


4th International Conference on Drug Discovery, Designing and Development

About Conference

International Conference on Drug Discovery, Designing and Development is scheduled to be held during June 27-28, 2018 at Vancouver, Canada. Drug Discovery conference includes a wide range of Keynote presentations, plenary talks, Symposia, Workshops, Exhibitions, Poster presentations and Career development programs

Conference series LLC Ltd Organizes 3000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series LLC Ltd website will provide you list and details about the conferences organize worldwide.

Why to Attend???

Drug Designing 2018 discuss various disciplines involved in Drug discovery and Innovative Drug Design, drug discovery and development, Nano Technology in Drug Discovery, Drug Discovery in Pre-clinical research, Clinical trials and Regulatory Affairs, Pharmaceutical Research and Development and many more. It also focusses on discussing the treatment strategies, risk management and consequences and challenges in drug design and discovery industry. It promotes better understanding by general public about the importance of drug discovery. The conference aims at promoting interaction among the researchers, students, industrial professionals, pharmacists from all around the globe. It is a campaign to create awareness about the recent advancements, researches, breakthroughs, technology developed in the area of drug discovery and development.

Drug Designing 2018 anticipates participants, renowned speakers and eminent delegates across the globe to be attending the conference to share their valuable presentation and galvanize the scientific community. Scientific people from all over the globe focused on learning about emerging technologies about Drug Discovery and Designing. This is a best globalized opportunity to reach the largest assemblage of participants from the scientific community and research. Make a splash with most recent techniques, developments and the newest updates in Drug Discovery and Development and receive name recognition at this 2-days event.

Who Should Attend and Who You’ll Meet

Directors/Senior Directors/Executive Directors
Vice Presidents/Senior Vice Presidents/ Executive Vice Presidents
Heads/Leaders/Partners of Pharma/Biotech and Medical Device industries
Hospitals professionals
Drug development and formulation scientists
Academic and Industrial Scientists and experts in drug discovery, formulation and delivery of drugs
Clinicians involved in the prescription and/or review of therapeutic agents
Regulatory and clinical scientists involved in drug development and drug registration
Clinical pharmacists
Education providers in pharmacy, pharmacology and toxicology
Students and postdoctoral fellows in all areas of the Pharmaceutical Sciences
Highlights of the conference:

300+ Participation (70 Industry: 30 Academia)
8+ Keynote Speakers
60+ Plenary Speakers
20+ Exhibitors
14 Innovative Educational Sessions
5+ Workshops
B2B Meetings

Drug Designing 2018 includes 16 Tracks/ Sessions and 70+ Sub-Tracks which covers all the aspects of Drug Discovery, Designing and Development. Drug Designing 2018 Scientific Committee proudly announces and welcomes all the participants across the globe to attend the “Drug Designing 2018” slated on June 27-28, 2018 at Vancouver, Canada.

The theme of the conference is “Challenges and Innovations in Drug Discovery and Development”

Track 1: Drug Discovery and Development

Drug discovery is the process through which potential new medicines are recognized and comprises an extensive range of scientific disciplines, including biology, chemistry and pharmacology. The integration of pharmacodynamics and pharmacokinetic parameters in non-clinical pharmacology studies is a key characteristic in drug discovery for efficacy and safety assessment, in the particular for the translation from the non-clinical to clinical field and process of drug discovery include the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy whereas modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability. The "final product" of drug discovery is a patent on the potential drug.

Track 2: Medicinal Chemistry in Modern Drug Discovery

The modern drug discovery process is an overview to the development of new drugs. Now a days new biological targets, methodologies and advanced computing have enhanced modern drug discovery and have given medicinal chemistry a more thoughtful skill set and toolkit to hold the nuances of disease pathophysiology. The medicinal chemistry related methodologies and a methodology in drug discovery improves the efficiency in drug discovery and lessening attrition. In drug designing, Structure-based drug design, and fragment –based drug design, natural product-based drug design, diversity-based drug design, and chemo genomics are applied.

Track 3: Natural products Drug Discovery

Natural products (secondary metabolites) have been more successful source of potential drug leads. Natural products still play a major role as starting material for drug discovery. There are several sources for natural products for drug discovery like plant sources, microbial sources, and marine sources. Natural products are very large in numbers with an excellent chemical diversity. Natural products discovery can be approached by using Cell-Based assays, Biochemical assays and newer drug discovery. Natural products have played a key role in Pharma research, as many medicines are either natural products or derivatives.

Track 4: Drug Discovery in Preclinical Research

The chief impartial of pre-clinical studies is to define the safe dose for first-in-man study and assess a product's safety profile. Pre-clinical development also recognized as pre-clinical studies and non-clinical studies .In the drug development, preclinical development, is a phase study which prior to earlier clinical trials can begin, and during which important possibility, iterative testing and drug safety data is composed. Generally, only one in every 5,000 compounds that arrives drug discovery to the stage of pre-clinical development befits as an approved drug. These pre-clinical studies involve local toxicity studies such as acute, sub-acute, chronic toxicity studies and systemic toxicity studies such as genotoxicity and carcinogenicity studies.

Track 5: Drug Delivery and Targeting

The drug delivery system active can regulate the pharmacological action of a drug persuading its pharmacokinetic and subsequent therapeutic profile. The drug delivery system employed plays a vital role in controlling the pharmacological effect of the drug as it can influence the pharmacokinetic profile of the drug, the rate of drug release, the site and duration of drug action and subsequently the side-effect profile. The purpose of any delivery system is to enhance or facilitate the action of therapeutic compounds. Ideally a drug delivery system could deliver the correct amount of drug to the site of action at the correct rate and timing, in order to maximize the desired therapeutic response. Specialized drug delivery systems constitute a relatively recent addition to the field of pharmaceutical technology.

Track 6: Cardiovascular Drug Discovery

Cardiovascular diseases are projected to affect populace across the world. Cardiovascular diseases contain diseases and disorders related to heart and blood vessels. Numerous drugs are accessible and are under development for treating cardiovascular diseases based on various signs such as arrhythmia, myocardial infarction, and atherosclerosis. The global cardiovascular drug has been involved into many drugs. Some of the major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and Angiotensin II receptor antagonists, and hypolipidemic drugs.

Track 7: Nanotechnology in Drug Discovery

Nanotechnology is a study of science and technology which targets to regulate matter at the atomic, molecular, and macromolecular level. New nanotechnologies could bring intense increases in the sensitivity of detection technology for research and diagnostic applications, improved imaging technologies, greater selectivity for drug delivery, and detailed insight into biological mechanisms and systems. Nano biosensors and Nano biochips are used to develop drug discovery and development. Nano scale assays can subsidize substantially to cost-saving in screening promotions. The practice of Nano scale delivery vehicles prominent to the discovery of optimally safe in talling to effective drug candidates, current and promising applications of Nano medicine include, drug delivery, in vitro diagnostics, in vivo imaging, therapy techniques, biomaterials, and tissue engineering .As recognition of the importance of this moving field, it is estimated that the global market of Nano scale applications in medical field might grow to $70 - $160 bn.

Track 8: Drug designing and Molecular Modelling

Drug design, frequently called as rational drug design, is the resourceful process of discovering new medications based happening the knowledge of a biological target. The saying "drug design" is to also known as ligand design. This molecule design will bind tightly to its target. While design techniques for prediction of binding affinity are practically successful but there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that must be enhanced before a ligand can become a safe and efficacious drug. The normal cost of developing new drug molecules and the period taken to market them is high. Molecular modelling methods also known as Computational methods. These techniques can be utilized to speed up drug discovery process for earning new drug molecules. Reliant on the context and the rigor, the subject is often stated to as ‘molecular graphics’, ‘molecular visualizations’, ‘computational chemistry’, or ‘computational quantum chemistry’.

Track 09-: Clinical Trials and Regulatory Affairs

Clinical trial generate data on safety and efficacy. Such consequent biomedical or behavioural research studies on human participants are designed to answer specific questions about biomedical or behavioural interferences, including new treatments such as novel vaccines, drugs, dietary supplements, and medical devices. These trials produce data on safety and efficacy. The regulatory affairs outsourcing market has been segmented into five major service sections .Those sections include regulatory affairs, clinical trial applications and product registrations, regulatory writing and publishing, regulatory consulting and legal representation and others. The market sections have been broadly scheduled on the source of their usefulness, efficacy, and generated revenue and geographic revenue.

Track 10: Pharmaceutical Research and Development

In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.

Track 11: Computational Molecular Biology

Computational Molecular Biology is a comparatively new science, with enormous growth since few years. Computational Biology is planned to afford a unique and in effect venue for the rapid publication of monographs, textbooks, edited collections, reference works, and lecture notes of the maximum quality. It deals with the key issues concerning analysis of genomes, sequences and structures. Bioinformatics is both parasol term for the body of biological studies that use computer programming as part of their methodology, as well as a reference to specific analysis "pipelines" that are frequently used, mostly in the field of genomics.

Track 12: Novel Therapeutics in Drug Designing

Nanotechnology is an evolving unparalleled technology. It has substantial use in the diagnosis and treatment of disease and is highly prospective towards to be used in foods, cosmetics and medical products. Nanoparticles assurance to increase in capability and complexity. They are used to enhance the pharmacokinetic and pharmacodynamics profiles of many drug molecules. Biodegradable nanoparticles are using in pharmaceutical formulations to release and transport the drug efficiently.

Track 13: Computer Aided Drug Design (CADD)

Molecular mechanics is most commonly used to estimate the strength of the intermolecular interaction between the small molecule and its biological target. It can also be used to provide semi-quantitative prediction of the binding affinity. This method will be able to predict affinity before a compound is synthesized and hence only one compound needs to be synthesized. Computational methods have accelerated finding by decreasing the number of iterations required and must often provide novel structures.

Track 14: Pharmaceutical Formulation

Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. Formulation studies are important to do a lot of formulation studies in order to detect the point of incorporation. Formulation studies must focus on other factors like particle size, polymorphism, pH and solubility, in order to check whether these factors will effect on bioavailability of the drug or not.

The drug must be combined with inactive ingredients by a method which ensures that the quantity of drug present is consistent in each dosage unit e.g. each tablet. The word formulation is often used in a way which includes dosage forms.

Track 15: Pharmaceutical Biotechnology and Clinical Drug Evaluation

The introduction of biotechnology-derived pharmaceuticals for clinical use has frequently required for the application of unique approaches to evaluating their safety in preclinical studies. There is abundant assortment among these products, which comprise the gene and cellular therapies, monoclonal antibodies, human-derived recombinant regulatory proteins, blood products, and vaccines. There will be distinctive product issues for many of the biological therapies that may definite precise modifications to protocol design and may raise additional safety concerns. Clinical trials are observations which are finished in clinical research and are accompanied only after they have received health authority/ethics committee approval in the country where approval of the therapy is required. These authorities are liable for screening the risk/benefit ratio of the trial. Their approval does not mean that the therapy is 'safe' or effective, only that the trial may be conducted.

Track 16: Pharmaceutical and Biomedical Analysis

Pharmaceutical and biomedical analysis deals with the diversified features of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. It is obvious throughout healthcare, from diagnosis and analysis to treatment and recovery, and has entered the public integrity though the propagation of implantable medical devices, such as pacemakers and artificial hips, to more futuristic technologies such as stem cell engineering and the 3-D printing of biological organs.

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for:
- Multiple participant discounts
- Price quotations or visa invitation letters
- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)
- Event sponsorship

Prices may go up any time. Service fees included in pricing.
This event is brought to you by:
Conference Series - NewYorkEventsList


Share with friends

Date and Time


Executive Airport Plaza Hotel & Conference Centre

7311 Westminster Highway , Richmond, BC

Vancouver, Canada


View Map

Refund Policy

No Refunds

Save This Event

Event Saved